10:00-10:05am EST
Welcome and Introduction
Nigel Russell, Director of Events, GenomeWeb
10:05-10:30am EST
Use of Automated Next-Generation Sequencing for Rapid Profiling of Myeloid Malignancies
Giovanni Insuasti, MD, Assistant Professor, Pathology, Wake Forest University School of Medicine; Pathologist, Atrium Health Wake Forest Baptist
Next-Generation Sequencing (NGS) plays a key role in the diagnosis, management and prognosis of myeloid neoplasms. The purpose of this talk is to share the experience about the implementation of an automated NGS platform on a large academic medical center and to describe the advantages and disadvantages of this technology.
10:35-11:05am EST
Keynote
Kashyap Patel, MD, Chief Executive Officer, Carolina Blood and Cancer Care Associates; President, Community Oncology Alliance
11:10am-12:10pm EST
The Evolving Field of Biomarker Testing in Solid Tumors: Integration of Precision Medicine into Community Oncology Practices
Stephen “Fred” Divers, MD, Chief Medical Officer, American Oncology Network; Andrew J. McKenzie, PhD, Vice President, Personalized Medicine, Sarah Cannon; Scientific Director, Genospace; James Reeves, MD, Medical Director, Clinical Research Program, Florida Cancer Specialists
Despite the recent advances in targeted- and immuno- therapy development, there remain significant challenges in broadly integrating, adopting, and standardizing precision oncology into clinical practice. Recent data suggest that less than 50% of lung cancers receive adequate biomarker testing, and those who do receive the proper testing may not be getting their results analyzed, annotated, and acted upon appropriately. To address this, several strategies and approaches have been adopted by community-based medical oncology organizations to democratize access to biomarker testing, appropriate targeted- and immune-therapies, and clinical trials. Herein we describe the strategies underway at several large community -based oncology practices, practice management companies, and clinical research institutes to integrate precision oncology into routine clinical care.
12:15pm-12:45pm EST
The Battle Royale Between Oncologists and Payers in Implementing Precision Oncology
Russell “Russ” Ingersoll, PhD, Chief Product Officer, Trapelo; Debra Patt, MD, PhD, MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives, Texas Oncology
Precision medicine is changing the way cancer is tested and treated in the US, but a lack of standardization and barriers to collaboration between oncologists, payers and genomic testing labs has been slowing its use. In fact, the gap between how oncologists and payers make oncology care decisions has never been greater, and it is impeding the application of life-saving therapies.
This “battle royale” between payers and oncologists must end to ensure cancer patients are getting the most appropriate precision testing and therapies at the right stage of their treatment journeys. But how? Join Dr. Debra Patt, M.D., MBA, PH.D., Health Economics and Health Services Research Oncologist and breast cancer expert at Texas Oncology and Russell Ingersoll, Ph.D. Chief Product Officer and pharmacology and toxicology expert at Trapelo Health for an in-depth discussion on the root causes, how we can bring stakeholders together and create a more modern prior authorization process that brings the right therapy to cancer patients more quickly.